Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Akorn has signed a five-year supply agreement with Fresenius Kabi for a novel premix product.
Subscribe to our email newsletter
Under the terms of the agreement, Akorn will be responsible for development, marketing and distribution of the premix product. Fresenius Kabi will manufacture the product at its intravenous solutions manufacturing facility in Halden, Norway. The product is expected to launch in 2012. Current product sales of this product in the US are in excess of $500 million. Akorn will own the ANDA.
Premix medications are ready to use intravenous drug products, which eliminate compounding steps in the pharmacy or at the point of care.
Arthur Przybyl, president and CEO of Akorn, said: “We look forward to partnering with Fresenius Kabi on this novel premix product. Additional niche products will be added that provide unique market value and fulfill customer needs.”